Skip to Content

Homology Medicines, Inc.

Company NameHomology Medicines, Inc.
Stock SymbolFIXX

In June 2019, Homology launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. The Company "reported encouraging safety and efficacy data from the dose-escalation portion of the trial" and claimed that the data showed HMI-102 "produced a sustained reduction in phenylalanine (Phe)."

 

Then, on July 21, 2020, Mariner Research published a report, alleging that Homology’s comments "conveniently ignor[ed] the implications to efficacy and the business." Citing data from a mouse study, the Phase 1/2 trial, and a key patient's Facebook posts, the report concluded that HMI-102 "therapy is showing zero efficacy even for a high dose patient," signifying that "the HMI-102 program is dead in the water." Moreover, citing internal emails and analyst reports, Mariner Research claimed Homology had selectively discussed the patient's Facebook posts with sell side analysts covering the Company and major investors.

 

On this news, Homology’s stock price fell $1.71 per share, or more than 10%, over three consecutive trading sessions to close at $14.77 per share on July 24, 2020, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Homology Medicines, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd